Literature DB >> 24412830

Incidence and risk factors for Contegra graft infection following right ventricular outflow tract reconstruction: long-term results.

Frederique Albanesi1, Nicole Sekarski2, Dimitrios Lambrou3, Ludwig K Von Segesser1, Denis A Berdajs4.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the risk factors associated with Contegra graft (Medtronic Minneapolis, MN, USA) infection after reconstruction of the right ventricular outflow tract.
METHODS: One hundred and six Contegra grafts were implanted between April 1999 and April 2010 for the Ross procedure (n = 46), isolated pulmonary valve replacement (n = 32), tetralogy of Fallot (n = 24), double-outlet right ventricle (n = 7), troncus arteriosus (n = 4), switch operation (n = 1) and redo of pulmonary valve replacement (n = 2). The median age of the patients was 13 years (range 0-54 years). A follow-up was completed in all cases with a median duration of 7.6 years (range 1.7-12.7 years).
RESULTS: There were 3 cases of in-hospital mortality. The survival rate during 7 years was 95.7%. Despite the lifelong endocarditis prophylaxis, Contegra graft infection was diagnosed in 12 (11.3%) patients at a median time of 4.4 years (ranging from 0.4 to 8.7 years). Univariate analysis of preoperative, perioperative and postoperative variables was performed and the following risk factors for time to infection were identified: female gender with a hazard ratio (HR) of 0.19 (P = 0.042), systemic-to-pulmonary shunt (HR 6.46, P < 0.01), hypothermia (HR 0.79, P = 0.014), postoperative renal insufficiency (HR 11.97, P = 0.015) and implantation of permanent pacemaker during hospitalization (HR 5.29, P = 0.075). In 2 cases, conservative therapy was successful and, in 10 patients, replacement of the infected valve was performed. The Contegra graft was replaced by a homograft in 2 cases and by a new Contegra graft in 8 cases. Cox's proportional hazard model indicated that time to graft infection was significantly associated with tetralogy of Fallot (HR 0.06, P = 0.01), systemic-to-pulmonary shunt (HR 64.71, P < 0.01) and hypothermia (HR 0.77, P < 0.01).
CONCLUSION: Contegra graft infection affected 11.3% of cases in our cohort, and thus may be considered as a frequent entity that can be predicted by both intraoperative and early postoperative factors. After the diagnosis of infection associated with the Contegra graft was confirmed, surgical treatment was the therapy of choice.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Endocarditis; Pulmonary valve; Ross operation; Xenograft

Mesh:

Year:  2014        PMID: 24412830     DOI: 10.1093/ejcts/ezt579

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

Review 1.  Infective endocarditis in paediatric population.

Authors:  Loay Eleyan; Ameer Ahmed Khan; Gledisa Musollari; Ashwini Suresh Chandiramani; Simran Shaikh; Ahmad Salha; Abdulla Tarmahomed; Amer Harky
Journal:  Eur J Pediatr       Date:  2021-04-14       Impact factor: 3.183

2.  Percutaneous pulmonary valve implantation as an alternative to repeat open-heart surgery for patients with pulmonary outflow obstruction: a reality in Singapore.

Authors:  Shakeel Ahmed Quereshi; Swee Chye Quek; Lik Wui Edgar Tay; Wei Luen James Yip; Ting Ting Low; Chin Ling William Yip; Kok Fai William Kong; Tiong Cheng Yeo; Huay Cheem Tan
Journal:  Singapore Med J       Date:  2018-11-29       Impact factor: 1.858

3.  Mid-term outcomes of Contegra implantation for the reconstruction of the right ventricular outflow tract to proximal branch pulmonary arteries: Japan multicentre study.

Authors:  Takaya Hoashi; Hajime Ichikawa; Keiichi Hirose; Naohiro Horio; Takahisa Sakurai; Hironori Matsuhisa; Yoshihiro Ohsima; Hajime Sakurai; Shingo Kasahara; Kisaburo Sakamoto
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-07-26

4.  Nationwide Registry-Based Analysis of Infective Endocarditis Risk After Pulmonary Valve Replacement.

Authors:  Clara Stammnitz; Dörte Huscher; Ulrike M M Bauer; Aleksandra Urban; Johannes Nordmeyer; Stephan Schubert; Joachim Photiadis; Felix Berger; Sabine Klaassen
Journal:  J Am Heart Assoc       Date:  2022-02-18       Impact factor: 5.501

5.  Decellularized fresh homografts for pulmonary valve replacement: a decade of clinical experience.

Authors:  Samir Sarikouch; Alexander Horke; Igor Tudorache; Philipp Beerbaum; Mechthild Westhoff-Bleck; Dietmar Boethig; Oleg Repin; Liviu Maniuc; Anatol Ciubotaru; Axel Haverich; Serghei Cebotari
Journal:  Eur J Cardiothorac Surg       Date:  2016-03-24       Impact factor: 4.191

Review 6.  Current development of bovine jugular vein conduit for right ventricular outflow tract reconstruction.

Authors:  Chenggang Li; Bo Xie; Ruizhe Tan; Lijin Liang; Zhaoxiang Peng; Qi Chen
Journal:  Front Bioeng Biotechnol       Date:  2022-08-04

7.  Risk factors for early adverse outcomes after bovine jugular vein conduit implantation: influence of oversized conduit on the outcomes.

Authors:  Dong-Hee Kim; Young Kern Kwon; Eun Seok Choi; Bo Sang Kwon; Chun Soo Park; Tae-Jin Yun
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-09-09

8.  Surgical Treatment of Infective Endocarditis in Pulmonary Position-15 Years Single Centre Experience.

Authors:  Daina Liekiene; Laurynas Bezuska; Palmyra Semeniene; Rasa Cypiene; Virgilijus Lebetkevicius; Virgilijus Tarutis; Jurate Barysiene; Kestutis Rucinskas; Vytautas Sirvydis
Journal:  Medicina (Kaunas)       Date:  2019-09-19       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.